Supplementary Figure S3 from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Figure S3. Early changes from baseline in ESR1 ctDNA VAFs. Absolute ESR1 VAF by giredestrant dose (A) or by clinical benefit (B) at baseline, C1D15 and C2D1. (A–B) Individual lines represent matched ESR1 ctDNA results from a single patient across time points. (C) Boxplots of absolute ESR1 VAF grouped by treatment and clinical benefit. (A–C) ESR1 VAF is represented as the sum of all detected ESR1 VAFs at each time point. The giredestrant 100 mg +palbociclib ±LHRH cohort includes three patients from the cardiac evaluation cohort who initiated single-agent giredestrant 100 mg on cycle 1, day –14, and then continued on giredestrant 100 mg +palbociclib on cycle 1, day 1. Relative change of ESR1 VAF from baseline by giredestrant dose (D) or by clinical benefit (E). (D–E) Only patients with detectable ESR1 VAF at baseline are included. Bars represent mean relative change with standard deviation; dots represent individual relative changes. (C–E) For patients with results from more than one ctDNA baseline sample, the sum ESR1 VAF from the sample collected closest to C1D1 was used for calculating relative change.